Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
NNX 0.035 +0.0% ABX 51.85 −0.7% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.99 +10.5% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.40 −0.5% SGZ 0.045 +0.0% S 0.155 +29.2% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% NNX 0.035 +0.0% ABX 51.85 −0.7% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.99 +10.5% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.40 −0.5% SGZ 0.045 +0.0% S 0.155 +29.2% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0%
Financings Routine +

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

Medicenna Secures $12.4M Lifeline Amidst Dilution Concerns and Clinical Milestones

By The Northwire Desk — AI Analysis May 28, 2026 · 09:10 MDNA · 0.425 MEDICENNA THERAPEUTICS CORP. J
Executive Summary
  • Medicenna Therapeutics Corp. announced the closing of a public offering raising CDN$4.44 million via 8,880,000 Units at CDN$0.50 per Unit.
  • Each unit includes one common share and one-half of one warrant (exercise price $0.65, expiry 3 years).
  • A separate structured financing agreement was entered into with Sorbie Bornholm LP and Sorbie Investments LLP for CDN$8.0 million.
  • The company issued compensation warrants to the sole agent, Bloom Burton Securities Inc., totaling 450,100 units (exercise price $0.50, expiry 2 years).
  • Proceeds are designated for clinical and regulatory development of lead programs MDNA11 and MDNA113, working capital, and general corporate purposes.
  • This closing follows the May 22, 2026 announcement of the prospectus supplement and investment term sheet which outlined these same terms.
Material Impact
  • The financing provides critical liquidity to extend cash runway beyond the previously stated mid-2026 limit, reducing immediate bankruptcy risk.
  • However, the dilution is significant: approximately 8.88 million new shares plus warrants from the public offering and Sorbie investment (16 million units).
  • The equity swap "Sharing Agreement" with Sorbie introduces volatility; proceeds are settled via 18 monthly tranches based on share performance against a benchmark price, creating potential future cash flow uncertainty or additional dilution if stock underperforms.
  • The market reaction to the announcement of terms (May 22) was negative, evidenced by the price drop from $0.66 (May 19) to $0.43 (May 27), suggesting investors priced in the dilutive nature before closing.
  • As a closing event for previously disclosed terms, this is not "genuinely new" information but confirms execution of the capital raise strategy.
MDNA · Price
Company Overview
  • Company: Medicenna Therapeutics Corp., a biopharmaceutical company focused on immunotherapy for cancer.
  • Flagship Project (MDNA11): A long-acting, "beta-enhanced not-alpha" IL-2 Superkine currently in Phase 1b/2 trials (ABILITY-1) and Phase 1b neoadjuvant trial (NEO-CYT).
  • Secondary Asset (MDNA113): First-in-class tumor-anchored anti-PD-1 x IL-2 bifunctional Superkine; preclinical data presented at AACR 2026 showed superior tolerability in non-human primates.
  • Third Asset (Bizaxofusp/MDNA55): IL-4 Empowered Superkine targeting recurrent glioblastoma; Phase 2b trial showed median OS of 13.6 months vs 7 months standard care.
  • Development Stage: MDNA11 is in clinical trials for advanced solid tumors and melanoma; MDNA113 is preclinical awaiting IND filing.
Read the original news release →

More from MEDICENNA THERAPEUTICS CORP. J

Jun 26, 2026 · 08:45

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Earnings Jun 11, 2026 · 07:00

Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms

M&A / Property Jun 03, 2026 · 07:00

ASCO Presentation Offers No New Catalysts as Dilutive Capital Raise Extends Runway Amid Steep Equity Erosion

Other May 22, 2026 · 07:00

Medicenna Files $13M Financing at Deep Discount as Cash Dwindles and Stock Spirals

Financings May 19, 2026 · 07:00

Financing Finalized at Discount as Dilution Concerns Weigh on Stock

Financings May 13, 2026 · 16:01

Cash Runway Expiry Triggers Dilutive Financing Despite Clinical Milestones

Financings